Compare Stocks: CRDL, TLRY, SPRY, and CRMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.80 +5.3%	$1.18	$0.88 ▼ $1.82	$208.59M	0.72	971,333 shs	1.73 million shs
CRMD CorMedix	$7.54 -7.4%	$8.14	$6.13 ▼ $14.96	$591.53M	1.5	1.19 million shs	2.70 million shs
SPRY ARS Pharmaceuticals	$5.65 -7.4%	$7.58	$4.91 ▼ $15.09	$561.06M	0.98	2.43 million shs	5.05 million shs
TLRY Tilray Brands	$4.67 -0.6%	$4.52	$3.67 ▼ $23.20	$636.07M	1.9	4.91 million shs	3.27 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	+5.26%	+26.76%	+62.16%	+36.36%	+61.43%
CRMD CorMedix	-7.37%	+1.34%	-10.45%	-0.13%	-37.58%
SPRY ARS Pharmaceuticals	-7.38%	-8.28%	-25.17%	-23.96%	-64.29%
TLRY Tilray Brands	-0.64%	+2.19%	+6.62%	-12.22%	-62.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.80 +5.3%	$1.18	$0.88 ▼ $1.82	$208.59M	0.72	971,333 shs	1.73 million shs
CRMD CorMedix	$7.54 -7.4%	$8.14	$6.13 ▼ $14.96	$591.53M	1.5	1.19 million shs	2.70 million shs
SPRY ARS Pharmaceuticals	$5.65 -7.4%	$7.58	$4.91 ▼ $15.09	$561.06M	0.98	2.43 million shs	5.05 million shs
TLRY Tilray Brands	$4.67 -0.6%	$4.52	$3.67 ▼ $23.20	$636.07M	1.9	4.91 million shs	3.27 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	+5.26%	+26.76%	+62.16%	+36.36%	+61.43%
CRMD CorMedix	-7.37%	+1.34%	-10.45%	-0.13%	-37.58%
SPRY ARS Pharmaceuticals	-7.38%	-8.28%	-25.17%	-23.96%	-64.29%
TLRY Tilray Brands	-0.64%	+2.19%	+6.62%	-12.22%	-62.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	2.33	Hold	$8.50	372.22% Upside
CRMD CorMedix	2.75	Moderate Buy	$15.00	98.94% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$28.20	399.12% Upside
TLRY Tilray Brands	2.50	Moderate Buy	$11.00	135.55% Upside

Current Analyst Ratings Breakdown

Latest CRDL, TLRY, SPRY, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	TLRY Tilray Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	TLRY Tilray Brands	TD Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/14/2026	TLRY Tilray Brands	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $5.00
7/7/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$14.00 ➝ $13.00
6/25/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$25.00 ➝ $24.00
6/24/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/1/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/28/2026	SPRY ARS Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$12.00 ➝ $30.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
CRMD CorMedix	$457.20M	1.29	$2.04 per share	3.69	$5.14 per share	1.47
SPRY ARS Pharmaceuticals	$116.93M	4.80	N/A	N/A	$1.16 per share	4.87
TLRY Tilray Brands	$915.45M	0.69	N/A	N/A	$13.68 per share	0.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	N/A
CRMD CorMedix	$163.05M	$2.14	3.52	754.00	N/A	40.49%	41.90%	21.30%	N/A
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-199.96%	-65.41%	N/A
TLRY Tilray Brands	-$121.40M	-$1.08	N/A	N/A	N/A	-13.11%	-7.76%	-5.59%	10/8/2026 (Estimated)

Latest CRDL, TLRY, SPRY, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
7/28/2026	Q4 2026	TLRY Tilray Brands	-$0.0120	-$0.43	-$0.4180	-$0.43	$246.30 million	$281.71 million
5/15/2026	Q1 2026	SPRY ARS Pharmaceuticals	-$0.53	-$0.61	-$0.08	-$0.61	$22.20 million	$22.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	N/A	5.55	4.39
CRMD CorMedix	0.33	2.97	2.74
SPRY ARS Pharmaceuticals	2.79	4.94	4.77
TLRY Tilray Brands	0.22	2.21	1.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
CRMD CorMedix	34.18%
SPRY ARS Pharmaceuticals	68.16%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
CRMD CorMedix	3.50%
SPRY ARS Pharmaceuticals	33.80%
TLRY Tilray Brands	0.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	115.89 million	109.80 million	Not Optionable
CRMD CorMedix	30	78.45 million	75.71 million	Optionable
SPRY ARS Pharmaceuticals	90	99.30 million	65.74 million	Optionable
TLRY Tilray Brands	3,595	136.20 million	135.06 million	Optionable

CRDL, TLRY, SPRY, and CRMD Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY): Balance Sheet Moves Take Focus

August 14 at 7:31 AM | kalkinemedia.comK

Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?

August 14 at 7:31 AM | finance.yahoo.com

Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.

August 14 at 7:31 AM | finance.yahoo.com

Montauk Brewing Company Announces New Collaboration with Morning Brew Inc.

August 13 at 7:00 AM | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.1% - Time to Sell?

August 12 at 5:39 PM | marketbeat.com

Why Tilray Brands (NASDAQ:TLRY) Keeps Drawing Attention Across Diversified Cannabis Markets?

August 11, 2026 | kalkinemedia.comK

Is Tilray Brands (NASDAQ:TLRY) the Cannabis Name Buzzing After Its Beverage Launch?

August 11, 2026 | kalkinemedia.comK

Tilray Brands (NASDAQ:TLRY) Stock Price Up 8.1% - Time to Buy?

August 11, 2026 | marketbeat.com

Tilray Brands stock rises as Curaleaf plots hostile takeover for Aurora

August 11, 2026 | invezz.comI

Hi*Ball® Energy Powers into the English Football League with Wolverhampton Wanderers Partnership

August 11, 2026 | finance.yahoo.com

Hi*Ball® Energy Powers into the English Football League with Wolverhampton Wanderers Partnership

August 11, 2026 | financialpost.comF

Breckenridge Distillery Turns Colorado’s Famous Palisade Peaches into a Fresh Pour of Summer with New Peach Whiskey

August 11, 2026 | finance.yahoo.com

Breckenridge Distillery Turns Colorado’s Famous Palisade Peaches into a Fresh Pour of Summer with New Peach Whiskey

August 11, 2026 | financialpost.comF

Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - What's Next?

August 10, 2026 | marketbeat.com

Tilray Brands Expects to Hit a Major Milestone for the Current Fiscal Year: $1 Billion in Annual Revenue. Here's How it Plans to Get There

August 10, 2026 | fool.com

Tilray to cease brewing at Terrapin site in US

August 10, 2026 | just-drinks.comJ

BrewDog Launches Park IPA Campaign to Make Punk IPA the Beer of London Summer Park Gatherings

August 10, 2026 | quiverquant.comQ

BrewDog Claims London’s Summer Park Season with ‘Park IPA’

August 10, 2026 | financialpost.comF

Top Cannabis Stocks To Follow Today - August 7th

August 9, 2026 | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) General Counsel Mitchell Gendel Buys 2,500 Shares

August 8, 2026 | insidertrades.com

Tilray Brands (TLRY) Gets Fresh Attention As Mollo Lite Launch Fuels The Value Debate

August 8, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, TLRY, SPRY, and CRMD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.80 +0.09 (+5.26%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.77 -0.03 (-1.44%)

As of 08/14/2026 07:34 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

CorMedix NASDAQ:CRMD

$7.54 -0.60 (-7.37%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.57 +0.03 (+0.42%)

As of 08/14/2026 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

ARS Pharmaceuticals NASDAQ:SPRY

$5.65 -0.45 (-7.38%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.61 -0.04 (-0.71%)

As of 08/14/2026 07:34 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Tilray Brands NASDAQ:TLRY

$4.67 -0.03 (-0.64%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.64 -0.03 (-0.56%)

As of 08/14/2026 07:58 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, TLRY, SPRY, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, TLRY, SPRY, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, TLRY, SPRY, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, TLRY, SPRY, and CRMD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

CorMedix NASDAQ:CRMD

ARS Pharmaceuticals NASDAQ:SPRY

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDL, TLRY, SPRY, and CRMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDL, TLRY, SPRY, and CRMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDL, TLRY, SPRY, and CRMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, TLRY, SPRY, and CRMD Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

CorMedix NASDAQ:CRMD

ARS Pharmaceuticals NASDAQ:SPRY

Tilray Brands NASDAQ:TLRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools